ATE253918T1 - Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel - Google Patents
Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittelInfo
- Publication number
- ATE253918T1 ATE253918T1 AT99403077T AT99403077T ATE253918T1 AT E253918 T1 ATE253918 T1 AT E253918T1 AT 99403077 T AT99403077 T AT 99403077T AT 99403077 T AT99403077 T AT 99403077T AT E253918 T1 ATE253918 T1 AT E253918T1
- Authority
- AT
- Austria
- Prior art keywords
- hymenialdisine
- derivatives
- production
- therapeutic agents
- gsk
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- QPCBNXNDVYOBIP-WHFBIAKZSA-N hymenialdisine Chemical compound NC1=NC(=O)C([C@@H]2[C@@H]3C=C(Br)N=C3C(=O)NCC2)=N1 QPCBNXNDVYOBIP-WHFBIAKZSA-N 0.000 title abstract 2
- ATBAETXFFCOZOY-UHFFFAOYSA-N hymenialdisine Natural products N1C(N)=NC(=O)C1=C1C(C=C(Br)N2)=C2C(=O)NCC1 ATBAETXFFCOZOY-UHFFFAOYSA-N 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 108091007914 CDKs Proteins 0.000 abstract 1
- 102000008122 Casein Kinase I Human genes 0.000 abstract 1
- 108010049812 Casein Kinase I Proteins 0.000 abstract 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 abstract 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99403077A EP1106180B1 (de) | 1999-12-08 | 1999-12-08 | Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE253918T1 true ATE253918T1 (de) | 2003-11-15 |
Family
ID=8242210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99403077T ATE253918T1 (de) | 1999-12-08 | 1999-12-08 | Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7098204B2 (de) |
| EP (2) | EP1106180B1 (de) |
| JP (1) | JP2004500356A (de) |
| AT (1) | ATE253918T1 (de) |
| AU (1) | AU2365701A (de) |
| CA (1) | CA2384982A1 (de) |
| DE (1) | DE69912808T2 (de) |
| ES (1) | ES2213996T3 (de) |
| WO (1) | WO2001041768A2 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2968701A (en) * | 2000-01-24 | 2001-07-31 | Genzyme Corporation | Jak/stat pathway inhibitors and the uses thereof |
| US6756385B2 (en) * | 2000-07-31 | 2004-06-29 | Pfizer Inc. | Imidazole derivatives |
| GT200100147A (es) * | 2000-07-31 | 2002-06-25 | Derivados de imidazol | |
| TW201041580A (en) | 2001-09-27 | 2010-12-01 | Alcon Inc | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma |
| US7521230B2 (en) * | 2002-10-16 | 2009-04-21 | Board Of Regents Of The University Of Nebraska | Nucleic acid encoding a Brain Derived Tau Kinase polypeptide and methods of use thereof |
| DE60323876D1 (de) * | 2002-12-17 | 2008-11-13 | Centre Nat Rech Scient | Verwendung von purinderivaten zur induktion der differenzierung überzähliger haarzellen und deiter-zellen im entwickelnden corti-organ zur behandlung von taubheit |
| US7423031B2 (en) * | 2003-05-01 | 2008-09-09 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| JP2007515940A (ja) * | 2003-05-08 | 2007-06-21 | ワイス | 関節炎及びその他の炎症性疾患の薬物標的としてのプロテインキナーゼｃゼータ |
| US7385055B2 (en) | 2003-05-19 | 2008-06-10 | Board Of Trustees Of Michigan State University | Preparation of hymenialdisine derivatives and use thereof |
| DE102004002885B4 (de) * | 2004-01-20 | 2007-03-15 | Johannes-Gutenberg-Universität Mainz | Neue medizinisch einsetzbare Pyrrolalkaloide: Verfahren zu ihrer Isolierung, Synthese, sie enthaltende Arzneimittel und deren Verwendung |
| EP2275096A3 (de) | 2005-08-26 | 2011-07-13 | Braincells, Inc. | Neurogenese durch modulation des Muscarinrezeptors |
| EP2258357A3 (de) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenese mit Acetylcholinesterasehemmer |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| EP2314289A1 (de) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba-rezeptor-vermittelte modulation von neurogenese |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| FR2899107B1 (fr) * | 2006-03-30 | 2008-06-13 | Neurokin Entpr Unipersonnelle | Utilisation de la (s)-roscovitine pour la fabrication d'un medicament |
| EP2021000A2 (de) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenese mittels angiotensin-modulation |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| CA2652339A1 (en) * | 2006-05-15 | 2007-11-22 | Senex Biotechnology, Inc. | Cdki pathway inhibitors as selective inhibitors of tumor cell growth |
| WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| ES2425179T3 (es) | 2006-10-25 | 2013-10-11 | The Rockefeller University | Métodos para el tratamiento de trastornos relacionados con beta-amiloide y composiciones para los mismos |
| US8304408B2 (en) | 2007-05-24 | 2012-11-06 | The Regents Of The University Of California | Wnt signaling inhibitors, and methods for making and using them |
| WO2009032194A1 (en) | 2007-08-31 | 2009-03-12 | Whitehead Institute For Biomedical Research | Wnt pathway stimulation in reprogramming somatic cells |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CN104193761B (zh) * | 2009-12-04 | 2017-10-17 | 桑诺维恩药品公司 | 多环化合物及其使用方法 |
| ES2728932T3 (es) | 2014-01-09 | 2019-10-29 | Intra Cellular Therapies Inc | Compuestos orgánicos |
| EP3210017B1 (de) | 2014-10-26 | 2021-10-06 | King Abdullah University Of Science And Technology | Alkaloide aus schwamm, gerüste zur hemmung des humanen immunschwächevirus (hiv) |
| US20180030095A1 (en) | 2015-02-13 | 2018-02-01 | George Robert Pettit | Silstatin compounds |
| WO2019094709A1 (en) | 2017-11-09 | 2019-05-16 | Pettit George R | Betulastatin compounds |
| KR102858286B1 (ko) * | 2023-01-26 | 2025-09-10 | 경희대학교 산학협력단 | 항생효과를 가지는 신규 유기-금속 복합체, 이를 포함하는 항생용 조성물 및 이의 제조방법 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5565448A (en) * | 1992-02-24 | 1996-10-15 | Smithkline Beecham Corporation | Medicament |
| JP3714685B2 (ja) * | 1994-05-18 | 2005-11-09 | 第一サントリーファーマ株式会社 | ハイメニアルディシン及びその誘導体並びにそれらの合成中間体の製造法並びにその合成中間体 |
| DE19500851A1 (de) | 1995-01-13 | 1996-07-18 | Werner & Pfleiderer Lebensmitt | Teigteil- und Wirk-Maschine |
| US5591740A (en) * | 1995-06-07 | 1997-01-07 | Osteoarthritis Sciences, Incorporated | Use of debromohymenialdisine for treating osteoarthritis |
| CA2216559A1 (en) * | 1997-09-25 | 1999-03-25 | Michel Roberge | G2 checkpoint inhibitors and assay |
| IL129178A0 (en) | 1999-03-25 | 2000-02-17 | Yeda Res & Dev | Induction of nerve generation |
| CN1202826C (zh) | 1999-08-05 | 2005-05-25 | 帝人株式会社 | 神经障碍治疗剂 |
| FR2798065B1 (fr) | 1999-09-02 | 2003-09-05 | Assist Publ Hopitaux De Paris | Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| US20050009876A1 (en) | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| CA2423192C (en) | 2000-09-20 | 2010-11-23 | Karolinska Innovations Ab | 1-azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors |
| TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
-
1999
- 1999-12-08 DE DE69912808T patent/DE69912808T2/de not_active Expired - Lifetime
- 1999-12-08 ES ES99403077T patent/ES2213996T3/es not_active Expired - Lifetime
- 1999-12-08 AT AT99403077T patent/ATE253918T1/de not_active IP Right Cessation
- 1999-12-08 EP EP99403077A patent/EP1106180B1/de not_active Expired - Lifetime
-
2000
- 2000-12-07 CA CA002384982A patent/CA2384982A1/en not_active Abandoned
- 2000-12-07 EP EP00987404A patent/EP1235578A2/de not_active Ceased
- 2000-12-07 US US10/149,115 patent/US7098204B2/en not_active Expired - Fee Related
- 2000-12-07 JP JP2001543113A patent/JP2004500356A/ja active Pending
- 2000-12-07 WO PCT/EP2000/012791 patent/WO2001041768A2/en not_active Ceased
- 2000-12-07 AU AU23657/01A patent/AU2365701A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1235578A2 (de) | 2002-09-04 |
| DE69912808T2 (de) | 2004-09-30 |
| EP1106180B1 (de) | 2003-11-12 |
| US20030105075A1 (en) | 2003-06-05 |
| US7098204B2 (en) | 2006-08-29 |
| WO2001041768A3 (en) | 2002-05-10 |
| CA2384982A1 (en) | 2001-06-14 |
| ES2213996T3 (es) | 2004-09-01 |
| EP1106180A1 (de) | 2001-06-13 |
| DE69912808D1 (de) | 2003-12-18 |
| AU2365701A (en) | 2001-06-18 |
| JP2004500356A (ja) | 2004-01-08 |
| WO2001041768A2 (en) | 2001-06-14 |
| WO2001041768A9 (en) | 2002-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69912808D1 (de) | Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel | |
| ATE361287T1 (de) | Neue indol-2-on derivate | |
| IS2293B (is) | Arýl sambrædd asapólýsýklísk efnasambönd | |
| ATE407928T1 (de) | Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung | |
| CY1108514T1 (el) | Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων | |
| TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
| MXPA04005444A (es) | Ureas de 2-aminobenzotiazoles como moduladores de adenosina. | |
| TR200100377T2 (tr) | Aß Protein üretimi inhibitörleri olarak sukinoilamino laktamlar. | |
| WO2007100366A3 (en) | Quinolone m1 receptor positive allosteric modulators | |
| PT2527315E (pt) | Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson | |
| WO2002085909A8 (en) | 9-deazaguanine derivatives as inhibitors of gsk-3 | |
| CY1106645T1 (el) | Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος | |
| DK1632483T3 (da) | Heterocykliske, substituerede carbonylderivater og deres anvendelse som dopamin-D3-receptorligander | |
| ATE245639T1 (de) | Acetylenderivate zur verwendung als schmerzstillendes oder entzündungshemmendes mittel | |
| TW200502221A (en) | Novel lactams and uses thereof | |
| CY1110391T1 (el) | Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους | |
| ATE367387T1 (de) | Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden | |
| TW200509933A (en) | Therapeutic agents | |
| BG104983A (en) | Aryl fused azapolycyclic compounds | |
| NO20023486D0 (no) | Forbindelser av pyrroltypen, perapater inneholdende forbindelser samt deres anvendelse for behandling av cancer- ogvirale sykdommer | |
| WO2000059489A3 (en) | Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites | |
| WO2005003103A3 (en) | 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases | |
| AU2972701A (en) | 3-aminopyrazole inhibitors of cyclin dependent kinases | |
| ATE453617T1 (de) | Substituierte n-arylbenzamide und verwandte verbindungen zur behandlung von amyloidkrankheiten und synukleinopathien | |
| TW200504036A (en) | Novel lactams and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |